BTCC
/
BTCC Square
/
thehindubusinessline
/
š Lupin (Buy): Why This Pharma Stock Could Outperform in Q3 2025
š Lupin (Buy): Why This Pharma Stock Could Outperform in Q3 2025
15
3
Wall Street's latest darling? Lupin gets a bullish broker call as generics rebound.
### The Case for Lupin
Analysts are betting big on this pharma underdogāFDA approvals and a streamlined pipeline could send shares soaring. Meanwhile, legacy drugmakers keep milking patent cliffs like 90s rock bands cashing in on reunion tours.
### Market Movers
With US generics demand spiking and Lupin's biosimilars gaining traction, this might be the contrarian play institutional investors missed. Short sellers are already covering positions.
### Bottom Line
While the stock's had more volatility than a crypto meme coin, the risk/reward looks compellingāif you can stomach pharma's version of 'decentralized finance': regulatory roulette.
By:
